作者: Karianne Risberg , Kathrine Røe Redalen , Linda Sønstevold , Tonje Bjørnetrø , Janne Sølvernes
DOI: 10.1186/S12885-016-2600-Y
关键词:
摘要: Background The use of targeted agents to impel dual inhibition anti-apoptotic mechanisms and mTOR-mediated pro-survival signaling in colorectal carcinoma (CRC) cell lines with KRAS or BRAF mutation has been shown induce apoptosis, a timely result given CRC entities harboring such mutations are need new therapies. Since comprises heterogeneous tumors predominant hypoxic components, we investigated effects an inhibitor Bcl-2 family proteins (ABT-737) combination mTOR (AZD8055)—collectively referred as combo-Rx, lines.